ATHERSYS INC (ATHX) rated Buy with price target $6 by Canaccord Adams
Canaccord Adams rated Buy ATHERSYS INC (NASDAQ: ATHX) on 08/01/2008, when the stock price was $2.70. Since
then, ATHERSYS INC has gained 40.37% as of 03/05/2014's recent price of $3.79. If you would have followed this Canaccord Adams's recommendation on ATHX, you would have gained 40.37% of your investment in 2042 days.
Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company?s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.
provides focused, actionable, idea-driven research, helping clients make informed investment decisions. Our 55 international analysts scour the globe for emerging and small to mid cap (US$1-2 billion market capitalization) growth opportunities, identifying value and exposing risk.
Our research team analyzes over 550 companies in eight sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. Our clients benefit from our thorough and sophisticated knowledge of the sectors we cover - Metals and Mining, Energy, Technology, Life Sciences, Real Estate, Consumer, Sustainability and Industrial Growth. We combine independent, actionable ideas, unique global perspective and unparalleled industry expertise. We believe it's evident in our research, and the foundation of our business.